论文部分内容阅读
上海“十一五”规划将生物医药产业作为支撑上海未来经济发展战略产业之一,发展目标:到2010年,争取实现20个创新药物的产业化,30个创新药物进行临床研究;涌现出15～20家年收入过10亿元的科技企业,形成2～3家年收入超百亿元的旗舰企业;全市生物医药产业年销售收入达到700亿元,逐步融入国际生物医药产业链和创新链,使上海成为在全球具有一定影响力的生物医药创新和产业化基地。上海科技中长期规划也明确将生物医药作为上海未来发展的重点领域。但是经过几年发展,目前上海生物医药产业的产值对上海的GDP贡献仍然不大,占上海GDP的2.8%,因此,课题组通过对上海生物医药产业发展经济指标分析,找出制约上海生物医药产业发展的原因。
Shanghai “Eleventh Five-Year Plan” will take the bio-pharmaceutical industry as one of the strategic industries supporting Shanghai’s future economic development and its development goal: to achieve the industrialization of 20 innovative drugs and 30 innovative drugs for clinical research by 2010; Out of 15 to 20 annual revenue of 1 billion yuan in science and technology enterprises, the formation of 2 to 3 annual revenues of over 10 billion yuan in the flagship enterprise; the city’s biomedical industry annual sales revenue reached 70 billion yuan, and gradually into the international bio-pharmaceutical industry chain and Innovation chain, so that Shanghai has become the world’s influential bio-pharmaceutical innovation and industrialization base. Shanghai Science and Technology Medium- and Long-term Plan also clearly defined biomedicine as a key area for Shanghai’s future development. However, after several years of development, Shanghai’s biopharmaceutical industry’s output contribution to Shanghai’s GDP is still modest at present, accounting for 2.8% of Shanghai’s GDP. Therefore, the research group analyzed the economic indicators of the development of Shanghai’s biopharmaceutical industry to find out the factors restricting Shanghai Biomedicine The reason of industrial development.